Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Apple Inc AAPL

Alternate Symbol(s):  N.AAPL

Apple Inc. designs, manufactures and markets smartphones, personal computers, tablets, wearables and accessories, and sells a variety of related services. Its product categories include iPhone, Mac, iPad, and Wearables, Home and Accessories. Its software platforms include iOS, iPadOS, macOS, watchOS, and tvOS. Its services include advertising, AppleCare, cloud services, digital content and payment services. It operates various platforms, including the App Store, that allow customers to discover and download applications and digital content, such as books, music, video, games and podcasts. It also offers digital content through subscription-based services, including Apple Arcade, Apple Fitness+, Apple Music, Apple News+ and Apple TV+. Its products include iPhone 15 Pro, iPhone 15, iPhone 14, iPhone 13, MacBook Air, MacBook Pro, iMac, Mac mini, Mac Studio, Mac Pro, and others. It also provides DarwinAI, which specializes in visual quality inspection using its Explainable AI platform.


NDAQ:AAPL - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Gowtheron Dec 04, 2021 12:05am
168 Views
Post# 34197781

FSD Pharma at the H.C. Wainwright 2nd Annual Psychedelics

FSD Pharma at the H.C. Wainwright 2nd Annual Psychedelics
 
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and accessible to view on the investor relations section of FSD’s website at https://ir.fsdpharma.com/news-events/events-presentations.
In addition, members of FSD Pharma’s management team will be available for one-on-one investor meetings during the conference.
For more information about the conference, or to schedule a one-on-one meeting with FSD's management team, please contact KCSA Strategic Communications at FSDPharma@kcsa.com or an H.C. Wainwright representative directly.



About FSD Pharma

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”) is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through the Company’s wholly owned subsidiary, Lucid, the Company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
 


Contacts
 
Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8888
Investor Relations: Email: skilmer@fsdpharma.com, Website: www.fsdpharma.com

<< Previous
Bullboard Posts
Next >>